The Queen Mary School, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, 999 Xuefu Road, Nanchang 330031, China.
Biomolecules. 2024 Aug 21;14(8):1038. doi: 10.3390/biom14081038.
The worldwide impact of liver diseases is increasing steadily, with a consistent upswing evidenced in incidence and mortality rates. Chronic liver diseases (CLDs) refer to the liver function's progressive deterioration exceeding six months, which includes abnormal clotting factors, detoxification failure, and hepatic cholestasis. The most common etiologies of CLDs are mainly composed of chronic viral hepatitis, MAFLD/MASH, alcoholic liver disease, and genetic factors, which induce inflammation and harm to the liver, ultimately resulting in cirrhosis, the irreversible final stage of CLDs. The latest research has shown that tripartite motif family proteins (TRIMs) function as E3 ligases, which participate in the progression of CLDs by regulating gene and protein expression levels through post-translational modification. In this review, our objective is to clarify the molecular mechanisms and potential therapeutic targets of TRIMs in CLDs and provide insights for therapy guidelines and future research.
肝脏疾病的全球影响正在稳步增加,其发病率和死亡率呈持续上升趋势。慢性肝脏疾病(CLD)是指肝脏功能的进行性恶化超过 6 个月,包括异常凝血因子、解毒功能衰竭和肝内胆汁淤积。CLD 的最常见病因主要包括慢性病毒性肝炎、MAFLD/MASH、酒精性肝病和遗传因素,这些因素会导致肝脏炎症和损伤,最终导致肝硬化,这是 CLD 的不可逆转的终末期。最新研究表明,三基序蛋白家族(TRIM)作为 E3 连接酶,通过翻译后修饰调节基因和蛋白质表达水平,参与 CLD 的进展。在这篇综述中,我们的目的是阐明 TRIM 在 CLD 中的分子机制和潜在治疗靶点,并为治疗指南和未来的研究提供思路。